Register for Digital Look

Company Announcements

Change of Adviser

Related Companies

By LSE RNS

RNS Number : 8529C
Venn Life Sciences Holdings PLC
25 January 2018
 

 

25 January 2018

Venn Life Sciences Holdings plc

("Venn" or the "Company" or the "Group")

 

Appointment of Nominated Adviser and Broker

 

Venn Life Sciences Holdings plc, the AIM drug development services organisation, announces the appointment of Cenkos Securities plc as its Nominated Adviser and Broker with immediate effect.

 

 

Enquiries:

 

Venn Life Sciences Holdings plc               

www.vennlifesciences.com

Allan Wood, Non-Executive Chairman

Tel: +44 (0)7785 325 898

Tony Richardson, Chief Executive Officer

Tel: +353 1 5499341



Cenkos (Nominated Adviser and Broker)

Tel: +44(0)20 7397 8900

Mark Connelly/Steve Cox (Corporate Finance)




Davy (ESM Adviser and Broker)

Tel: +353 1 679 6363

Fergal Meegan / Matthew de Vere White (Corporate Finance)




Hybridan LLP ( Joint Broker)

Tel: +44 (0)20 3764 2341

Claire Louise Noyce


 

About Venn Life Sciences: Venn Life Sciences is an Integrated Drug Development Partner offering a unique combination of drug development expertise and clinical trial design and management to pharmaceutical, biotechnology and medical device organisations. Venn have dedicated operations in France, Germany, the Netherlands, the UK, Ireland with partners across Europe and the US.

 

Further information in relation to Venn Life Sciences is available on their website - www.vennlifesciences.com

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
APPVZLFLVFFBBBE

Top of Page